Published in final edited form as:

Biochemistry. 2010 June 15; 49(23): 4760–4765. doi:10.1021/bi9020555.

The N-terminus of Glycogen Phosphorylase *b* is Not Required for Activation by AMP[†]

Andrew N. Bigley[‡] and Gregory D. Reinhart^{*}

Department of Biochemistry and Biophysics, Texas A&M University and Texas AgriLife Research, College Station TX, 77843

Abstract

The, so far unsuccessful, search for selective effective inhibitors of glycogen phosphorylase for the treatment of type II diabetes has made phosphorylase an active target of research for the last twenty years. Many crystallographic structures of phosphorylase are currently available to aid in this research. However, those structures have been interpreted, at least in part, based on work done with a proteolytically derived form of phosphorylase that lacked the N-terminus (phosphorylase *b'*). It has been reported that phosphorylase *b'* shows no allostery, neither homotropic nor heterotropic. The original report on phosphorylase *b'* examined the allosteric characteristics over very narrow ranges of effector and substrate concentrations, and reported the presence of proteolytic cleavages in addition to the removal of the N-terminus. We have applied molecular biological techniques to generate a truncate lacking the N-terminus with known primary structure, and we have established conditions to fully quantify the allosteric effect of AMP on glycogen phosphorylase *b*. We report here for the first time the full thermodynamic effect of AMP on phosphorylase *b*. Our findings with a truncate lacking the N-terminus show that the effect of AMP binding does not depend on the N-terminus.

Glycogen phosphorylase was one of the first enzymes recognized as being allosterically regulated, as well as the first case of regulation by phosphorylation (1-3). The phosphorylation of phosphorylase *b* at serine 14 converts the enzyme to the more active phosphorylase *a*. Activation by phosphorylation as well as allosteric activation by AMP are well established. However, over the last twenty years muscle phosphorylase has continued to be studied as a model for the regulation of liver glycogen phosphorylase, which is linked to type II diabetes (4-7). Unfortunately to date, this approach has yielded no therapeutics able to effectively exploit phosphorylase for the treatment of diabetes.

[†]This work was supported by NIH grant GM33216, the Robert A. Welch Foundation grant A1543, and the Chemistry-Biology Interface training grant, T32GM008523, from the NIH.

^{*}Author to whom correspondence should be addressed. Gregory D. Reinhart, Phone: (979) 862-2263. Fax: (979) 845-4295. gdr@tamu.edu.

[‡]Current address: Department of Chemistry, Texas A&M University

¹Abbreviations:

AMP	adenosine-5'-monophosphate
EDTA	Ethylenediaminetetraacetic acid
PMSF	phenylmethylsulfonyl fluoride
SDS	sodium dodecyl sulfate
NADP	nicotinamide adenine dinucleotide phosphate

Recognition that muscle phosphorylase was activated by phosphorylation at serine 14, led to much early interest in the role of the N-terminus in the activation of phosphorylase (8,9). The work done to establish the role of the N-terminus was published in 1968 and led to the formation of phosphorylase *b'*, a form of the enzyme that had the first 16 residues removed via proteolysis (8). The reported results implied that all of the allosteric responsiveness in phosphorylase was lost in the absence of the N-terminus. Specifically, it was found that AMP did not affect the affinity for phosphate and phosphate did not affect the affinity for AMP. These findings led to the conclusion that the N-terminus was responsible for transmitting the allosteric signal in phosphorylase *b*. The conclusions drawn from phosphorylase *b'* were and have remained the basis for interpreting the crystallographic structures of glycogen phosphorylase (10-12). It must be noted, however, that phosphorylase *b'* was derived by limited proteolysis of enzyme purified from rabbit muscle, and that additional effects on the primary structure of the enzyme were present as confirmed by polyacrylamide gel electrophoresis that yielded a diffuse band when stained for either protein or phosphorylase activity (8). Given that modern experimental techniques, particularly in molecular biology and data analysis, have advanced the ability to specifically address the role of the N-terminus of glycogen phosphorylase, we have undertaken this study to evaluate the significance of the N-terminus of glycogen phosphorylase *b* in the activation by AMP. We report here, for the first time, the full magnitude of the effect of AMP on glycogen phosphorylase *b*. We also show that the N-terminal truncate, Δ 2-17, of rabbit muscle glycogen phosphorylase retains all of the heterotropic and homotropic cooperativity observed in wild-type phosphorylase. However, Δ 2-17 has a reduced affinity for both AMP and phosphate. In addition, we were able to test the proteolytically derived phosphorylase *b'* under our experimental conditions. These data yield results that are comparable to the original findings with phosphorylase *b'*.

Materials and Methods

Phosphorylase *b* was obtained from bacterial expression of the recombinant rabbit muscle glycogen phosphorylase gene in the plasmid pTACTAC as previously described (13). Purified proteins were stored at 4° C and generally used within one week. β -glycerophosphate was from Sigma-Aldrich (St. Louis, MO) or USB (Cleveland, OH). Restriction enzymes were from New England Biolabs (Beverly, MA). Ion exchange chromatography resins were from Amersham Biosciences (Piscataway, NJ). Size exclusion resin, glycogen phosphorylase kinase, trypsin, and soybean trypsin inhibitor were from Sigma-Aldrich. Glucose-6-phosphate dehydrogenase was from Roche Applied Sciences (Indianapolis, IN). Phosphoglucomutase was from Roche Applied Sciences or Sigma-Aldrich. Rabbit liver glycogen used in this study was purchased from Sigma-Aldrich and was used as purchased. Glycogen was assayed for AMP prior to use with a coupled enzyme assay, and no detectable contamination was observed. Other chemicals were from Sigma-Aldrich.

Mutagenesis/Molecular Biology

The plasmid pTACTAC with the gene for wild-type glycogen phosphorylase from rabbit muscle inserted between NdeI and HindIII sites as previously described was used as the starting template for mutagenesis (13). The truncate Δ 2-17 was created by using Quik Change Site Directed Mutagenesis Kit (Stratagene, LaJolly, CA) to introduce a second NdeI cut site positioning the starting ATG at codon 17. The resulting plasmid was digested to completion with NdeI and gel purified to remove the DNA sequence between codons 1 and 17. The plasmid was then re-ligated to obtain the plasmid with a phosphorylase gene missing the DNA residues coding for amino acids 2 through 17. The nucleotide sequences over the region of interest were verified via DNA sequencing at the Gene Technology Laboratory at Texas A&M University.

Protein Expression and Purification

Wild-type and mutant phosphorylase were expressed from plasmid pTACTAC as previously described (13) with the exception that the growth was carried out in *E.coli* strain DF1020 (*pro-82*, *glnV44*(AS), Δ pfkB201, *recA56*, *endA1*, Δ (*rhaD-pfkA*)200, *thi-1*, *hsdR17*) (14,15) for 48 hr at 27°C in 1.5 L cultures that were inoculated with 40ml of culture grown to saturation at 37°C in the absence of inducer. Cell pellets from expression were stored at -80°C prior to protein purification. Protein purification was carried out with modifications of previously described methods (13). Briefly for wild-type, cell pellets from 1.5-3 L of culture were thawed and resuspended in 75 mL of resuspension buffer (50 mM β -glycerophosphate (pH 7.0), 30 mM β -mercaptoethanol, 1 mM EDTA, 0.2 mM PMSF, 0.7 μ g/mL pepstatin A, 0.5 μ g/mL leupeptin, 0.01% benzamidine). Cells were lysed by sonication until the OD₆₀₀ was approximately 1/10th of the starting value. Debris was pelleted by centrifugation at 14,000 g for 45 min. The supernatant was brought to 0.5% polyethylenimine by addition of a 10% solution (40 mM β -glycerophosphate, 10% polyethylenimine), and stirred on ice for 30 min. The precipitate was removed by centrifugation at 14,000 g for 45min. Solid (NH₄)₂SO₄ was added to the supernatant to 50% saturation, and stirred on ice for 20 min. The precipitated protein was recovered by centrifugation at 14,000 g for 30min. The pellet was resuspended in 25 mL of column buffer (25 mM β -glycerophosphate (pH 7.0), 1 mM β -mercaptoethanol, 1 mM EDTA, 0.2 mM PMSF, 0.01% Benzamidine), and dialyzed against three changes of the same buffer. Protein was then run over DEAE-Sepharose fast flow and SP-Sepharose Fast Flow columns run in tandem. Fractions from load and wash showing activity were pooled and used for subsequent kinetic and fluorescence experiments.

For Δ 2-17, the purification procedure followed was the same as above until the chromatography step. Δ 2-17 was loaded on a Q-Sepharose Fast Flow column and eluted with a 0-300 mM KCl gradient in column buffer. The cleanest fractions (as assessed by 10% SDS-polyacrylamide gel electrophoresis) with activity were pooled, dialyzed to remove salt, and loaded on a DEAE-Sepharose Fast Flow column. Elution was done with a 0-300 mM KCl gradient in column buffer. The cleanest fractions with activity were pooled and dialyzed to remove salt prior to use in kinetic and fluorescence studies. Protein was quantified using Pierce BCA protein assay.

Phosphorylase *a* and Phosphorylase *b*'

Phosphorylase *a* was produced and isolated utilizing purified phosphorylase *b* and commercially available phosphorylase kinase as previously described (16). Phosphorylase *b*' was made from phosphorylase *a* following the protocol of Graves (8).

Kinetic Measurements

Glycogen phosphorylase activity was followed in the direction of glycogen degradation at 25°C utilizing phosphoglucomutase and glucose-6-phosphate dehydrogenase in a coupled enzyme assay system to link the degradation of glycogen to the production of NADPH, which was followed at 340 nm on a Beckman 600 series UV/VIS spectrophotometer. Assays were carried out in a 600 μ L reaction volume containing 50 mM PIPES (pH6.8), 100 μ M EDTA, 5 mg/mL rabbit liver glycogen, 0-5 mM AMP, 0-300 mM potassium phosphate, 360 μ M NADP, 4 μ M glucose-1,6-bisphosphate, 10 mM MgCl₂, 6.7 U/mL phosphoglucomutase, 3 U/mL glucose-6-phosphate dehydrogenase. Changes in ionic strength due to varying phosphate concentrations were compensated for by the addition of appropriate amounts of KCl to maintain an ionic strength of approximately 0.69 M. Temperature was maintained within 1°C by a circulating water bath. The assay mixes were preincubated at 25°C, and the reaction was initiated by addition of appropriately diluted glycogen phosphorylase.

Steady State Fluorescence

Spectral measurements were collected on an SLM-4800 instrument with a Phoenix upgrade package from ISS (Champaign, IL). Spectra were collected with a 295 nm excitation wavelength at 25 °C in a 1 cm by 1 cm cuvette. Excitation slits were set to 2 nm, and emission slits were set to 8 nm. All measurements were collected with protein in column buffer. The same buffer without protein was used as a blank to correct the spectra. For experiments with AMP, 2 mM AMP was added to the blank as well as the sample.

Data Analysis

Initial velocity data were plotted as titrations for both phosphate and AMP, and individual titration curves were fit to the Hill equation to determine $K_{1/2}$ and Hill number (17). The measured Hill numbers for AMP binding at low concentrations of phosphate (< 40 mM for wild-type, <20 mM for $\Delta 2-17$ and phosphorylase b') from multiple experiments were averaged, and the average values were used to estimate the homotropic coupling between AMP sites in the absence of phosphate per equation 1 (18).

$$Q_{\text{AMP}} = \left[\frac{n_H}{2 - n_H} \right]^2 \quad (1)$$

where Q_{AMP} is the homotropic coupling quotient in AMP binding in the absence of phosphate and n_H is the average of multiple determinations of the Hill number for AMP binding at limiting low concentrations of phosphate (see Table 1). Analogous approaches were used to quantify the homotropic coupling quotient for AMP binding in the saturating presence of phosphate ($Q_{\text{AMP}/\text{P}_i}$), as well as the homotropic coupling quotient for phosphate binding at low (< 3 μM) and saturating concentrations of AMP (Q_{P_i} and $Q_{\text{P}_i}/\text{AMP}$ respectively).

Quantification of the heterotropic coupling between AMP and phosphate was carried out by fitting $K_{1/2}$ for phosphate as a function of AMP concentration to equation 2 (18). The values for homotropic coupling quotients for AMP binding, Q_{AMP} and $Q_{\text{AMP}/\text{P}_i}$ respectively, appearing in equation 2 were fixed to the values established utilizing equation 1 as just described.

$$K_{1/2} = K_{\text{P}_i}^0 \left[\frac{K_{\text{AMP}}^0{}^2 + 2K_{\text{AMP}}^0 [\text{AMP}] + Q_{\text{AMP}} [\text{AMP}]^2}{K_{\text{AMP}}^0{}^2 + 2K_{\text{AMP}}^0 Q_{\text{AMP}/\text{P}_i} \left[\frac{Q_{\text{AMP}}}{Q_{\text{AMP}/\text{P}_i}} \right]^{1/2} [\text{AMP}] + Q_{\text{AMP}/\text{P}_i}{}^2 Q_{\text{AMP}} [\text{AMP}]^2} \right]^{1/2} \quad (2)$$

where $K_{\text{P}_i}^0$ is the dissociation constant for phosphate in the absence of AMP. K_{AMP}^0 is the dissociation constant for the first equivalent AMP in the absence of phosphate, and $Q_{\text{AMP}/\text{P}_i}$ is the apparent heterotropic coupling quotient between AMP and phosphate².

The measured coupling quotients were converted to the free energy of coupling by the relationship between free energy and the coupling quotient given in equation 3.

$$\Delta G_{\text{coupling}} = -RT \ln Q \quad (3)$$

²The apparent value of $Q_{\text{AMP}/\text{P}_i}$ includes terms that reflect the homotropic coupling between the two substrate (P_i) binding sites in the absence and presence of bound AMP (18).

where $\Delta G_{\text{coupling}}$ is the free energy of coupling, R is the gas constant, T is the temperature, and Q is the coupling quotient of interest.

Activity Gels

Equal units of activity for wild-type and $\Delta 2-17$ glycogen phosphorylase *b* were applied to a 7.5% nondenaturing polyacrylamide gel and electrophoresed at 100 V for 2 hr on ice. As previously described, gels were incubated with 1% glycogen, 20 mM glucose-1-phosphate, 10 mM AMP in 50 mM PIPES buffer (pH 6.8) for AMP activation, or 1% glycogen 30 mM glucose-1-phosphate, 0.6 M $(\text{NH}_4)_2\text{SO}_4$ in 50 mM PIPES (pH 6.8) for sulfate activation (19). Incubation was carried out for 4 hr at room temperature. Following incubation gels were stained with a saturated solution of I_2 and photographed.

Results

Wild-Type Expression and Kinetics

Glycogen phosphorylase when expressed in *E.coli* is pure *b* form due to the lack of phosphorylase kinase. Wild-type was successfully expressed in *E.coli* DF1020 with similar yields to those previously reported (13). Titrations were carried out from 0 to 330 mM phosphate and 0-5 mM AMP. There is little to no effect on V_{max} for the enzyme upon addition of AMP while there is a dramatic effect on the affinity for phosphate. The replots of Hill number vs. phosphate or AMP allow the quantification of the homotropic cooperativity (Figure 3 and Table 1). Once the values for homotropic effects in AMP binding are established the replot of $K_{1/2}$ for phosphate vs. AMP can be fit to equation 2 and the coupling between AMP and phosphate can be quantified (Figure 1 and Table 1). This experimental approach allows for the measurement of activity even in the absence of AMP.

$\Delta 2-17$ Expression and Kinetics

Mutation of the gene for rabbit muscle glycogen phosphorylase allows for the creation of a modified protein that lacks the N-terminus ($\Delta 2-17$). The modified protein was successfully created, expressed, and purified. When the kinetics of the $\Delta 2-17$ mutant are measured, it displays a reduced affinity for AMP and phosphate as can be observed by the curve being shifted up and to the right in Figure 1 (also see Table 1). A clear dependence of the affinity for phosphate on the presence of AMP is observed, and conversely there is a clear dependence of the affinity for AMP on the presence of phosphate (Figures 1 and 2). Comparing the free energies of coupling in Table 1 it can be seen that there is slightly more interaction observed between AMP and phosphate binding with the $\Delta 2-17$ mutant compared to wild-type. Absence of the N-terminus clearly did not alleviate the heterotropic cooperativity in phosphorylase; on the contrary it is actually significantly enhanced relative to wild-type (Figure 1). The $\Delta 2-17$ enzyme also retains homotropic cooperativity with respect to both AMP and phosphate as reported in Table 1. To rule out the possibility of significantly altered secondary or tertiary structure in the $\Delta 2-17$ mutant, the intrinsic tryptophan fluorescence emission spectrum was recorded with excitation at 295 nm. The spectrum of $\Delta 2-17$ matched the spectrum of wild-type for both apo and with 2 mM AMP (data not shown). To test the ability of sulfate to activate $\Delta 2-17$, wild type and $\Delta 2-17$ were electrophoresed on 7.5% nondenaturing polyacrylamide gels. After reaction in the direction of glycogen synthesis by incubation with glycogen and glucose-1-phosphate, the gels were stained with iodine. Although AMP activates both wild-type and $\Delta 2-17$, $\Delta 2-17$ is not activated by sulfate (Figure 4).

Phosphorylase *b'*

To assess the differences between our findings with $\Delta 2-17$ and the originally published results in the absence of the N-terminus, we created phosphorylase *b'* from WT phosphorylase *a*

according to the original protocols (8). As previously reported, phosphorylase *b'* had a higher affinity for phosphate and AMP (Figure 1 and Table 1). However, there is still a substantial dependence of the affinity for phosphate on the presence of AMP. Interestingly, the slope of the transition region is much reduced with respect to both WT and $\Delta 2-17$, which might suggest why this activation was previously overlooked given the relative small concentration range of AMP used (8). In agreement with the previous work (8), there is no evidence for cooperativity in binding of phosphate at any concentration of AMP. At low phosphate concentrations, the Hill number for AMP is approximately 0.56 ± 0.03 indicating significant negative homotropic cooperativity in AMP binding. (Figure 3B) The Hill number returns to unity at higher concentrations of phosphate, indicating that this is a real case of negative homotropic cooperativity.

Discussion

Wild-Type Phosphorylase

Previously, phosphorylase *b* has been held to be inactive without AMP present (1,2,10), but under the experimental conditions used in this study, activity can be measured and the affinity for phosphate can be determined even in the absence of AMP. These data, when analyzed with linkage analysis rather than simply using a model that assumes an equilibrium between active and inactive forms of the enzyme, allow the complete quantification of the allostery in glycogen phosphorylase *b* with respect to AMP and phosphate. Many previous reports have shown the activation by AMP, but none have quantified the extent of coupling (8,10,13). This report provides a complete analysis of the extent of heterotropic coupling between phosphate and AMP in glycogen phosphorylase *b*.

$\Delta 2-17$ and phosphorylase *b'*

The results with the truncate $\Delta 2-17$ are in clear disagreement with the previously reported loss of cooperativity in phosphorylase *b'* (8). Loss of affinity for both substrate and effector is evident, but there is no loss, rather an enhancement, in the apparent heterotropic coupling (Figure 1). Similarly, it is clear that substantial homotropic cooperativity with both AMP and phosphate has been retained in the absence of the N-terminus. In light of these findings, the long standing proposal that the N-terminus transmits the allosteric signal across the subunit interface becomes highly improbable. The possibility that these differences are due to the trivial cause of different experimental conditions has been ruled out by examination of phosphorylase *b'*. When phosphorylase *b'* was tested under the same conditions as $\Delta 2-17$, results similar to those originally reported were found, confirming that there are different heterotropic and homotropic cooperativities in $\Delta 2-17$ and phosphorylase *b'*. The likely source of these differences is the use of proteolysis to generate phosphorylase *b'*. The original publication describing phosphorylase *b'* reported the presence of multiple cleavages that were apparent on SDS-PAGE in addition to the removal of the N-terminus (8). These additional cleavages were assumed to be inconsequential at the time. However, the finding that $\Delta 2-17$, which is of known primary structure, retains both homotropic and heterotropic cooperativity indicates that the additional cleavage sites in phosphorylase *b'* have significant effects. Irrespective of these differences, examining phosphorylase *b'* over a much larger concentration range of AMP shows that there is a great deal of heterotropic activation retained nonetheless. The two variants lacking the N-terminus therefore both show that allosteric activation by AMP is present in the absence of the N-terminus, though it is much reduced with phosphorylase *b'* (Figure 1). The conclusion that the N-terminus is not required for the activation by AMP is therefore unavoidable. It appears that the N-terminus probably does have a role in establishing the binding characteristics of apo phosphorylase *b*, since the affinities for phosphate and AMP are greatly altered in its absence. However that role is independent of any role in the allosteric coupling in the enzyme, which is not greatly disturbed.

It has been a long standing theory that the activation of phosphorylase proceeds via the same mechanism regardless of what the activation (1,10). The N-terminus is clearly implicated in activation by phosphorylation and by high concentrations of sulfate (20,21). Of course, phosphorylase cannot be activated by phosphorylation in the absence of the N-terminus, but activation by sulfate is also dependent on the N-terminus (Figure 4) (21). While the high concentrations of sulfate required for activation make quantitative comparison to effects of AMP difficult due to the potential complications of non-specific ionic strength effects, previous structural studies have shown that the activation by sulfate proceeds via an interaction with both the N-terminus and the phosphoserine recognition site (21). The lack of activation by sulfate in the absence of the N-terminus (Figure 4) provides a strong indication that the mechanism of activation with phosphorylation may in fact be distinct from the activation by AMP.

Conclusions

Our understanding of the functional characteristics of allosteric activation of glycogen phosphorylase has to date been largely based on investigations with a proteolytically derived enzyme of unknown primary structure looking at relatively narrow concentration ranges of substrates and AMP (8). The new findings reported here indicate that, contrary to the conclusions obtained from those investigations, heterotropic AMP activation of phosphate binding is if anything somewhat enhanced when the N-terminus is cleanly removed through mutagenesis. The positive homotropic cooperativities in the binding of AMP and phosphate are also retained. The interpretations of the structural changes that give rise to the allosteric activation of glycogen phosphorylase should be reevaluated in the light of these new findings.

Acknowledgments

We would like to thank Dr. Robert Fletterick for the generous contribution of the plasmid pTACTAC that was used in this study.

References

1. Cori GT, Colowick SP, Cori CF. The action of nucleotides in the disruptive phosphorylation of glycogen. *J. Biol. Chem* 1938;123:381–389.
2. Krebs EG, Fischer EH. The phosphorylase *b* to *a* converting enzyme of rabbit skeletal muscle. *Biochim. Biophys. Acta* 1956;20:150–157. [PubMed: 13315361]
3. Newgard CB, Hwang PK, Fletterick RJ. The family of glycogen phosphorylases: Structure and function. *Crit. Rev. Biochem. Mol* 1989;24:69–99.
4. Martin JL, Veluraja K, Ross K, Johnson LN, Fleet GWJ, Ramsden NG, Bruce I, Orchard MG, Oikonomakos NG, Papageorgious AC, Leonidas DD, Tsitoura HS. Glucose analogue inhibitors of glycogen phosphorylase: The design of potential drugs for diabetes. *Biochemistry* 1991;30:10101–10116. [PubMed: 1931942]
5. Gregoryiou M, Noble MEM, Watson KA, Garman EF, Krulle TM, De La Fuente C, Fleet FWJ, Oikonomakos NG, Johnson LN. The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 Å resolution and 100 K: The role of the water structure and its contribution to binding. *Protein Sci* 1998;7:915–927. [PubMed: 9568898]
6. Lu Z, Bohn J, Bergeron R, Deng Q, Ellsworth KP, Geissler WM, Harris G, McCann PE, McKeever B, Myer RW, Saperstein R, Willoughby CA, Yau J, Chapman K. A new class of glycogen phosphorylase inhibitors. *Bioorg. Med. Chem. Lett* 2003;13:4125–4128. [PubMed: 14592521]
7. Barker DJ, Greenhaff PL, MacInnes A, Timmons JA. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction. *Diabetes* 2006;55:1855–1861. [PubMed: 16731853]

8. Graves DJ, Mann SAS, Philip G, Oliveira RJ. A probe into catalytic activity and subunit assembly of glycogen phosphorylase: Desensitization of allosteric control by limited tryptic digestion. *J. Biol. Chem* 1968;243:6090–6098. [PubMed: 5723454]
9. Carty TJ, Tu J-I, Graves DJ. Regulation of glycogen phosphorylase: Role of the peptide region surrounding the phosphoserine residue in determining enzyme properties. *J. Biol. Chem* 1975;250:4980–4985. [PubMed: 1150650]
10. Barford D, Hu S-H, Johnson LN. Structural mechanism for glycogen phosphorylase control by phosphorylation and AMP. *J. Mol. Biol* 1991;218:233–260. [PubMed: 1900534]
11. Browner MF, Hwang PK, Fletterick RJ. Cooperative binding is not required for activation of muscle phosphorylase. *Biochemistry* 1992;31:11291–11296. [PubMed: 1445866]
12. Lukacs CM, Oikonomakos NG, Crowther RL, Hong L-N, Kammlott RU, Levin W, Li S, Liu C-M, Lucas-McGrady D, Pietranico S, Reik L. The crystal structure of human muscle glycogen phosphorylase a with bound glucose and AMP: An intermediate conformation with T-state and R-state features. *Proteins* 2006;63:1123–1126. [PubMed: 16523484]
13. Browner MF, Rasor P, Tugendreich S, Fletterick RJ. Temperature sensitive production of rabbit muscle glycogen phosphorylase in *Escherichia coli*. *Protein Eng* 1991;4:351–357. [PubMed: 1857717]
14. Daldal F. Molecular cloning of the gene for phosphofructokinase-2 of *Escherichia coli* and the nature of a mutation, *pfkBI*, causing a high level of the enzyme. *J. Mol. Biol* 1983;168:285–305. [PubMed: 6310120]
15. Hellinga HW, Evans PR. Nucleotide sequence and high-level expression of the major *Escherichia coli* phosphofructokinase. *Eur. J. Biochem* 1985;149:363–373. [PubMed: 3158524]
16. Buchbinder JL, Luong CBH, Browner MF, Fletterick RJ. Partial activation of muscle phosphorylase by replacement of serine 14 with acidic residues at the site of regulatory phosphorylation. *Biochemistry* 1997;36:8039–8044. [PubMed: 9201951]
17. Hill AV. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. *J. Physiol-London* 1910;40:iv–vii.
18. Reinhart GD. Linked function origins of cooperativity in a symmetrical dimer. *Biophys Chem* 1988;30:159–172. [PubMed: 3416042]
19. Proux D, Dryfus J-C. Phosphorylase isozymes in tissue: Prevalence of liver type in man. *Clin Chim Acta* 1973;48:167–172. [PubMed: 4758881]
20. Leonidas DD, Oikonomakos NG, Papageorgiou AC, Xenakis A, Cazianis CT, Bem F. The ammonium sulfate activation of phosphorylase *b*. *FEBS Lett* 1990;261:23–27. [PubMed: 2155134]
21. Leonidas DD, Oikonomakos NG, Papageorgiou AC. Sulfate activates phosphorylase *b* by binding to the Ser (P) site. *Biochim. Biophys. Acta* 1991;1076:305–307. [PubMed: 1900202]

Figure 1.

Replot of $K_{1/2}$ for phosphate as a function of AMP for wild-type and N-terminal truncates. Wild-type ($\bullet$), $\Delta 2-17$ ($\circ$), and Phosphorylase b' ($\square$) are shown with standard errors. $K_{1/2}$ data were determined from phosphate titrations fit with the Hill equation. Lines represent the best fit to equation 2 with values for homotropic coupling quotients for AMP fixed to the values determined from the Hill numbers observed in AMP titrations at high and low phosphate. All experiments were carried out with constant ionic strength at 25° C and with 5 mg/mL glycogen present.

Figure 2. Line plot of $K_{1/2}$ for AMP as a function of phosphate. Wild-type (λ), $\Delta 2-17$ ($\circ$), and Phosphorylase b' ($\square$) are shown with standard errors. Data generated under constant ionic strength at 25°C with 5mg/ml glycogen.

Figure 3.

Replots of Hill number vs the other ligand for wild-type and N-terminal truncates. (A) Replot of Hill number for phosphate vs AMP. (B) Replot of Hill number for AMP vs phosphate. Wild-type is shown as filled circles ($\bullet$). $\Delta 2-17$ is shown as open circles ($\circ$). Phosphorylase b' is shown as open squares ($\square$).

Figure 4. Activity gels with Wild-type and $\Delta 2-17$ Glycogen Phosphorylase b. Activity shown by 4hr incubation of roughly equal units of activity of wild-type and $\Delta 2-17$ in (A) 1% glycogen, 20 mM glc-1-phosphate, 10 mM AMP or (B) 1% glycogen, 20 mM glc-1-phosphate, and 1 M $(\text{NH}_4)_2\text{SO}_4$. Stain developed by incubation with iodine.

Table 1Kinetic constants and coupling free energies for wild-type (WT *b*), $\Delta 2-17$, and phosphorylase *b'* (*b'*)

	WT <i>b</i>	$\Delta 2-17$	<i>b'</i>
$K_{P_i}^0$ (mM) ^a	259±3	848±29	129±10
K_{AMP}^0 (mM) ^a	0.43±0.01	5.8±0.4	0.033±0.005
n_H (<i>P_i</i>) ^b	1.95±0.05 (8)	1.81±0.04 (5)	1.00±0.03 (11)
n_H (AMP) ^c	1.52±0.03 (20)	1.79±0.02 (9)	0.56±0.03 (10)
ΔG_{P_i-AMP} (kJ/mol) ^d	-7.5±0.4	-10±2	-6±1
ΔG_{P_i} (kJ/mol) ^e	-18± 4	-11±2	0.0
$\Delta G_{P_i/AMP}$ (kJ/mol) ^e	-1.4± 0.2	-0.2±0.1	0.0
ΔG_{AMP} (kJ/mol) ^f	-5.9± 4	-11.5±0.6	4.6±0.8
$\Delta G_{AMP/P_i}$ (kJ/mol) ^f	-0.9± 0.4	-7±2	-0.39±0.07

^a Dissociation constants and heterotropic coupling free energy determined from replots of $K_{1/2}$ for phosphate as a function of AMP.

^b Average value of Hill number in phosphate binding at low AMP. Reported as mean ± standard error (n), where n is number of independent experimental values averaged.

^c Average value of Hill number in AMP binding at low phosphate. Reported as mean ± standard error (n), where n is number of independent experimental values averaged.

^d ΔG_{P_i-AMP} is coupling free energy between AMP and phosphate, which is calculated from the heterotropic coupling quotient.

^e ΔG_{P_i} and $\Delta G_{P_i/AMP}$ are homotropic couplings in absence and saturating presence of AMP respectively.

^f ΔG_{AMP} and $\Delta G_{AMP/P_i}$ are homotropic coupling free energy for AMP in absence and saturating presence of phosphate respectively. Homotropic free energies calculated from the average Hill numbers at high and low concentrations of other ligand.